Work

Prefrontal Cortex Activation and Stopping Performance Underlie the Beneficial Effects of Atomoxetine on Response Inhibition in Healthy Volunteers and Those With Cocaine Use Disorder

Year: 2021

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Biological Psychiatry Cognitive Neuroscience and Neuroimaging

DOI: 10.1016/j.bpsc.2021.08.010

Authors: Peter Zhukovsky, Sharon Morein-Zamir, Hisham Ziauddeen, Emilio Fernandez-Egea, Chun Meng, Ralf Regenthal, Barbara J. Sahakian, Edward T. Bullmore, Trevor W. Robbins, Jeffrey W. Dalley, Karen D. Ersche

Institutions: University of Cambridge, Anglia Ruskin University, Cambridgeshire and Peterborough NHS Foundation Trust, Leipzig University, GlaxoSmithKline (United Kingdom), University Medical Center Hamburg-Eppendorf

Language: English

Topic: Neural and Behavioral Psychology Studies

Subfield: Cognitive Neuroscience

Field: Neuroscience

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Wellcome Trust, National Institute for Health and Care Research, Medical Research Council, UCLH Biomedical Research Centre, NIHR Cambridge Biomedical Research Centre

Awards: NIHR Senior Investigator Award, Institutional Strategic Support Fund PHASE 2 FY2014/16, Atomoxetine as a pharmacological treatment for chronic cocaine and heroin abusers, NIHR Senior Investigator Award, Refurbishment of the Herschel Smith building for Clinical Research in Cognitive Neuroscience at Cambridg University

OpenAlex ID: W3197002911

FWCI: 1.387

Cites: 83

Cited by: 14

Related to: 10